Loading...

Spark Therapeutics

DB:272
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
272
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Spark Therapeutics has significant price volatility in the past 3 months.
272 Share Price and Events
7 Day Returns
0.6%
DB:272
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
59.9%
DB:272
-7.4%
DE Biotechs
-5.6%
DE Market
272 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Spark Therapeutics (272) 0.6% -1.8% 164.7% 59.9% 198.5% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 272 outperformed the Biotechs industry which returned -7.4% over the past year.
  • 272 outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
272
Industry
5yr Volatility vs Market

Value

 Is Spark Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Spark Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Spark Therapeutics.

DB:272 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 16 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:272
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (2.03%))
1.319
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.32
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.319 * 5.96%)
8.09%

Discounted Cash Flow Calculation for DB:272 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Spark Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:272 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.09%)
2019 -124.33 Analyst x3 -115.03
2020 -162.00 Analyst x2 -138.66
2021 -101.50 Analyst x2 -80.37
2022 -15.00 Analyst x1 -10.99
2023 180.00 Analyst x1 122.00
2024 302.49 Est @ 68.05% 189.68
2025 446.80 Est @ 47.71% 259.19
2026 596.31 Est @ 33.46% 320.03
2027 736.39 Est @ 23.49% 365.64
2028 857.99 Est @ 16.51% 394.13
Present value of next 10 years cash flows $1,305.61
DB:272 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $857.99 × (1 + 0.23%) ÷ (8.09% – 0.23%)
$10,938.39
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10,938.39 ÷ (1 + 8.09%)10
$5,024.70
DB:272 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,305.61 + $5,024.70
$6,330.31
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,330.31 / 37.93
$166.91
DB:272 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:272 represents 0.88217x of NasdaqGS:ONCE
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88217x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 166.91 x 0.88217
€147.24
Value per share (EUR) From above. €147.24
Current discount Discount to share price of €97.63
= -1 x (€97.63 - €147.24) / €147.24
33.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Spark Therapeutics is available for.
Intrinsic value
34%
Share price is €97.63 vs Future cash flow value of €147.24
Current Discount Checks
For Spark Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Spark Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Spark Therapeutics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Spark Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Spark Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:272 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.11
NasdaqGS:ONCE Share Price ** NasdaqGS (2019-04-24) in USD $110.67
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Spark Therapeutics.

DB:272 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ONCE Share Price ÷ EPS (both in USD)

= 110.67 ÷ -2.11

-52.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spark Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Spark Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Spark Therapeutics's expected growth come at a high price?
Raw Data
DB:272 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -52.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts
19.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Spark Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Spark Therapeutics's assets?
Raw Data
DB:272 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $13.17
NasdaqGS:ONCE Share Price * NasdaqGS (2019-04-24) in USD $110.67
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:272 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ONCE Share Price ÷ Book Value per Share (both in USD)

= 110.67 ÷ 13.17

8.4x

* Primary Listing of Spark Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spark Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Spark Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Spark Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Spark Therapeutics expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Spark Therapeutics expected to grow at an attractive rate?
  • Spark Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Spark Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Spark Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:272 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:272 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts 19.4%
DB:272 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 16 Analysts 36.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:272 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:272 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 614 162 7
2022-12-31 435 -149 -105 8
2021-12-31 269 -151 -126 12
2020-12-31 173 -176 -173 16
2019-12-31 99 -97 -193 15
DB:272 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 65 -71 -79
2018-09-30 59 -55 -75
2018-06-30 50 -72 -93
2018-03-31 26 -68 -248
2017-12-31 12 -155 -253
2017-09-30 21 -156 -228
2017-06-30 20 -125 -196
2017-03-31 20 -106 -150
2016-12-31 20 -80 -124
2016-09-30 21 -70 -93
2016-06-30 21 -59 -77
2016-03-31 21 -46 -63

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Spark Therapeutics's earnings are expected to grow by 19.4% yearly, however this is not considered high growth (20% yearly).
  • Spark Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:272 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below

All data from Spark Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:272 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.35 28.05 -2.72 6.00
2022-12-31 -2.38 0.33 -5.37 5.00
2021-12-31 -2.74 7.08 -7.49 10.00
2020-12-31 -4.21 -1.01 -7.36 15.00
2019-12-31 -4.99 -3.62 -6.46 17.00
DB:272 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.11
2018-09-30 -2.05
2018-06-30 -2.56
2018-03-31 -7.11
2017-12-31 -7.63
2017-09-30 -7.13
2017-06-30 -6.39
2017-03-31 -5.05
2016-12-31 -4.29
2016-09-30 -3.40
2016-06-30 -3.00
2016-03-31 -2.53

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Spark Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Spark Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Spark Therapeutics has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Spark Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Spark Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Spark Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Spark Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Spark Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Spark Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Spark Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:272 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 64.73 -78.82 124.60 125.25
2018-09-30 58.98 -75.39 128.88 118.94
2018-06-30 50.17 -93.04 126.22 125.46
2018-03-31 26.47 -247.57 123.20 132.53
2017-12-31 12.07 -253.48 111.12 135.16
2017-09-30 20.96 -228.50 90.95 130.80
2017-06-30 20.36 -196.05 76.36 113.84
2017-03-31 20.17 -150.36 60.31 100.86
2016-12-31 20.18 -123.65 48.07 86.38
2016-09-30 21.08 -92.97 38.47 76.81
2016-06-30 21.08 -77.31 32.88 66.22
2016-03-31 21.08 -62.97 28.54 55.95
2015-12-31 22.06 -47.76 23.35 46.03
2015-09-30 5.48 -51.33 19.18 35.66
2015-06-30 4.18 -41.19 14.83 28.51
2015-03-31 2.89 -31.02 10.53 21.30
2014-12-31 0.63 -25.03 7.86 16.35
2014-09-30 0.02 -80.41 7.36 13.08
2014-06-30 0.02 -75.51 5.78 9.75
2013-12-31 -68.73 2.86 5.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Spark Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Spark Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Spark Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Spark Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Spark Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Spark Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Spark Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Spark Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Spark Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Spark Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Spark Therapeutics Company Filings, last reported 3 months ago.

DB:272 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 496.51 85.41 453.61
2018-09-30 549.88 84.89 590.48
2018-06-30 583.74 35.37 647.23
2018-03-31 479.67 35.75 587.55
2017-12-31 513.62 36.22 520.17
2017-09-30 570.40 1.30 478.70
2017-06-30 228.16 1.38 215.79
2017-03-31 289.55 1.45 253.69
2016-12-31 330.28 1.53 296.17
2016-09-30 359.52 1.58 306.65
2016-06-30 385.63 0.00 332.21
2016-03-31 279.17 0.00 274.97
2015-12-31 290.54 0.00 293.53
2015-09-30 191.70 0.00 212.16
2015-06-30 205.49 0.00 223.05
2015-03-31 216.92 0.00 234.41
2014-12-31 55.21 0.00 74.57
2014-09-30 62.72 0.00 67.27
2014-06-30 68.69 0.00 73.12
2013-12-31 3.37 0.00
  • Spark Therapeutics's level of debt (17.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 17.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Spark Therapeutics has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Spark Therapeutics has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -22.4% per year.
X
Financial health checks
We assess Spark Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Spark Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Spark Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Spark Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Spark Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Spark Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Spark Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:272 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:272 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Spark Therapeutics has not reported any payouts.
  • Unable to verify if Spark Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Spark Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Spark Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Spark Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Spark Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Spark Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Spark Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Spark Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Marrazzo
COMPENSATION $4,910,292
AGE 39
TENURE AS CEO 6.3 years
CEO Bio

Mr. Jeffrey D. Marrazzo, also known as Jeff, M.B.A., M.P.A. is a Co-Founder of Spark Therapeutics, Inc. (a/k/a, Spark Therapeutics, LLC) and has been its Chief Executive Officer since 2013. Mr. Marrazzo served as President at Spark Therapeutics, Inc. He is an experienced entrepreneur dedicated to curing disease through genomic medicine. Mr. Marrazzo was part of the founding management of Generation Health, Inc., a pharmacogenomics medicines company that was acquired by CVS Caremark in 2009 and a senior member of the business development and finance teams at Tengion, a venture-backed regenerative medicine company that went public in 2010. He served as Chief Business Officer of Molecular Health AG. He served as Vice President of Sales & Business Development at Generation Health, Inc. Most recently, Mr. Marrazzo launched the U.S. division of Molecular Health, Inc., securing capital and recruiting a management team for this emerging leader in personalized cancer therapy. Throughout his career, he has helped raise or place more than $150 million in venture capital and has led or co-led the formation of novel strategic partnerships with the FDA, Quest Diagnostics, GE Healthcare and SAP. Previously, he served as healthcare advisor to former Pennsylvania Governor Edward G. Rendell and as an IBM management consultant to global pharmaceutical companies. He has also advised investment firms such as Goldman Sachs, Safeguard Scientifics and BioAdvance. He has been a Director of Spark Therapeutics, Inc since 2013. Mr. Marrazzo holds a dual M.B.A./M.P.A. from The Wharton School and Harvard University, a program which he founded and B.A. in Economics and B.S.E. in systems science and Engineering from the University of Pennsylvania.

CEO Compensation
  • Jeff's compensation has increased whilst company is loss making.
  • Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Spark Therapeutics management team in years:

4.7
Average Tenure
47
Average Age
  • The tenure for the Spark Therapeutics management team is about average.
Management Team

Jeff Marrazzo

TITLE
Co-Founder
COMPENSATION
$5M
AGE
39
TENURE
6.3 yrs

Kathy High

TITLE
Co-Founder
COMPENSATION
$2M
AGE
66
TENURE
4.6 yrs

Stephen Webster

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
57
TENURE
4.8 yrs

Joe La Barge

TITLE
Chief Legal Officer & Secretary
COMPENSATION
$2M
AGE
47
TENURE
5.3 yrs

Dan Faga

TITLE
Chief Business Officer
COMPENSATION
$2M
AGE
38
TENURE
2.9 yrs

J. Wright

TITLE
Scientific Co-Founder
AGE
59

Jean Bennett

TITLE
Scientific Co-Founder and Advisor

Bev Davidson

TITLE
Scientific Co-Founder and Advisor

Federico Mingozzi

TITLE
Chief Scientific Officer
AGE
44
TENURE
1.6 yrs

Ryan Asay

TITLE
Head of Investor Relations
Board of Directors Tenure

Average tenure and age of the Spark Therapeutics board of directors in years:

4.9
Average Tenure
58
Average Age
  • The tenure for the Spark Therapeutics board of directors is about average.
Board of Directors

Steven Altschuler

TITLE
Chairman
COMPENSATION
$285K
AGE
65
TENURE
5.5 yrs

Jeff Marrazzo

TITLE
Co-Founder
COMPENSATION
$5M
AGE
39
TENURE
5.9 yrs

Kathy High

TITLE
Co-Founder
COMPENSATION
$2M
AGE
66
TENURE
4.6 yrs

Lars Ekman

TITLE
Director
COMPENSATION
$269K
AGE
68
TENURE
4.9 yrs

Vinnie, Vin Milano

TITLE
Director
COMPENSATION
$259K
AGE
54
TENURE
4.8 yrs

Lota Zoth

TITLE
Director
COMPENSATION
$264K
AGE
58
TENURE
3.3 yrs

Charles Sigal

TITLE
Director
COMPENSATION
$262K
AGE
66
TENURE
5.3 yrs

Anand Mehra

TITLE
Director
COMPENSATION
$260K
AGE
42
TENURE
4.9 yrs

Rob Perez

TITLE
Director
AGE
54
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
01. Mar 19 Sell The Children's Hospital Of Philadelphia Foundation, Endowment Arm Company 27. Feb 19 27. Feb 19 -2,000,000 €99.36 €-198,721,800
X
Management checks
We assess Spark Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Spark Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company’s gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company’s preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Details
Name: Spark Therapeutics, Inc.
272
Exchange: DB
Founded: 2013
$3,750,319,461
37,926,590
Website: http://www.sparktx.com
Address: Spark Therapeutics, Inc.
3737 Market Street,
Suite 1300,
Philadelphia,
Pennsylvania, 19104,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ONCE Common Stock Nasdaq Global Select US USD 30. Jan 2015
DB 272 Common Stock Deutsche Boerse AG DE EUR 30. Jan 2015
LSE 0L8L Common Stock London Stock Exchange GB USD 30. Jan 2015
Number of employees
Current staff
Staff numbers
368
Spark Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:50
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.